Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1959 1
1960 1
1962 1
1963 5
1964 1
1965 2
1966 4
1967 2
1968 2
1969 1
1970 3
1971 3
1972 3
1973 5
1974 9
1975 4
1976 6
1977 4
1978 12
1979 7
1980 14
1981 17
1982 17
1983 17
1984 21
1985 26
1986 32
1987 29
1988 24
1989 29
1990 35
1991 33
1992 43
1993 42
1994 34
1995 51
1996 57
1997 38
1998 43
1999 37
2000 48
2001 50
2002 42
2003 54
2004 75
2005 59
2006 76
2007 65
2008 58
2009 57
2010 81
2011 73
2012 71
2013 93
2014 86
2015 86
2016 99
2017 67
2018 85
2019 101
2020 127
2021 135
2022 134
2023 108
2024 106
2025 45

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,548 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators. van der Heijden MS, et al. Among authors: tomita y. N Engl J Med. 2023 Nov 9;389(19):1778-1789. doi: 10.1056/NEJMoa2309863. Epub 2023 Oct 22. N Engl J Med. 2023. PMID: 37870949 Clinical Trial.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. Among authors: tomita y. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Reply.
Suzuki M, Nagai N, Shinoda H, Uchida A, Kurihara T, Tomita Y, Kamoshita M, Iyama C, Tsubota K, Ozawa Y. Suzuki M, et al. Among authors: tomita y. Am J Ophthalmol. 2016 Sep;169:295-296. doi: 10.1016/j.ajo.2016.06.018. Epub 2016 Jul 15. Am J Ophthalmol. 2016. PMID: 27427198 No abstract available.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G, McDermott DF, Castellano D, Choueiri TK, Donskov F, Gurney H, Oudard S, Richardet M, Peltola K, Alva AS, Carducci M, Wagstaff J, Chevreau C, Fukasawa S, Tomita Y, Gauler TC, Kollmannsberger CK, Schutz FA, Larkin J, Cella D, McHenry MB, Saggi SS, Tannir NM. Motzer RJ, et al. Among authors: tomita y. Cancer. 2020 Sep 15;126(18):4156-4167. doi: 10.1002/cncr.33033. Epub 2020 Jul 16. Cancer. 2020. PMID: 32673417 Free PMC article. Clinical Trial.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Among authors: tomita y. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.
Perioperative therapies for urological cancers.
Inokuchi J, Yokomizo A, Nishiyama N, Kitamura H, Eto M, Nishiyama H, Tomita Y. Inokuchi J, et al. Among authors: tomita y. Jpn J Clin Oncol. 2020 Apr 7;50(4):357-367. doi: 10.1093/jjco/hyaa013. Jpn J Clin Oncol. 2020. PMID: 32115649 Review.
Advanced Bladder Cancer: Changing the Treatment Landscape.
Bilim V, Kuroki H, Shirono Y, Murata M, Hiruma K, Tomita Y. Bilim V, et al. Among authors: tomita y. J Pers Med. 2022 Oct 20;12(10):1745. doi: 10.3390/jpm12101745. J Pers Med. 2022. PMID: 36294884 Free PMC article. Review.
Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors.
Yuno A, Lee MJ, Lee S, Tomita Y, Rekhtman D, Moore B, Trepel JB. Yuno A, et al. Among authors: tomita y. Methods Mol Biol. 2018;1709:423-441. doi: 10.1007/978-1-4939-7477-1_29. Methods Mol Biol. 2018. PMID: 29177675 Review.
Reply.
Imasaka KI, Tomita Y. Imasaka KI, et al. Among authors: tomita y. Ann Thorac Surg. 2018 Oct;106(4):1258-1259. doi: 10.1016/j.athoracsur.2018.06.010. Epub 2018 Jul 17. Ann Thorac Surg. 2018. PMID: 30028979 No abstract available.
2,548 results